Children's Oncology Program

The clinical oncology program at Children’s National has 20 faculty members who are engaged in clinical research. The program participates in several research consortia including the Children’s Oncology Group (COG), Pediatric Brain Tumor Consortium (PBTC), Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium (TACL), and the Cooperative Ependymoma Research Network (CERN).

Children’s National researchers hold several leadership positions in the COG. Dr. Reaman was the first group Chair of COG from 2000-2010. Jeffrey Dome, MD, serves as the COG Principal Investigator for Children’s National, Chair of the COG Renal Tumor Committee, and Chair of the AREN0321 study for high-risk renal tumors. Anne Angiolillo, MD, and Reuven Schore, MD, serve as the Study Chair and Vice-Chair, respectively, of the AALL0932 study for standard-risk acute lymphoblastic leukemia (ALL), the largest therapeutic study within the COG. Holly Meany, MD, is the Chair for the upcoming COG study for intermediate-risk neuroblastoma. Shanna Jacobs, MD, is on the steering committee of the COG Cancer Control Committee. Children’s National is one of a select group of 21 institutions in North America to be included in the COG Phase I consortium, allowing patients with recurrent and refractory tumors access to the newest agents. Dr. Angiolillo serves as Principal Investigator, while Dr. Kim serves as the Co-Principal Investigator. Children’s National was one of the founding members of the Pediatric Brain Tumor Consortium (PBTC), a NIH-funded consortium consisting of eight member institutions. The PBTC is dedicated to developing novel therapies for children with pediatric central nervous system cancers through innovative biology-based early phase clinical trials. Brian Rood, MD, and Roger Packer, MD, co-chair the phase I PBTC-031 trial investigating PTC299, an anti-angiogenic agent in children with relapsed brain tumors. Lindsay Kilburn, MD, chairs the PBTC-031 phase II trial testing capecitabine and radiation in diffuse intrinsic pontine glioma and serves on the PBTC Data Safety Monitoring Board.

Children’s National investigators also develop phase I and II studies that are administrated outside the context of the large consortia. Dr. Meany is the Principal Investigator of a phase I study of sorafenib and irinotecan for recurrent solid tumors and brain tumors. This limited institutional study is funded by grants from the Clinical and Translational Science Institute at Children’s National (CTSI-CN), the American Society of Clinical Oncology (ASCO), and the Pablove Foundation. The Children’s Hospital of Philadelphia, Boston Children’s Hospital/Dana Farber Cancer Institute, and the National Cancer Institute are participating in this Children’s National-led study. Integrated with the study is a study of Patient Reported Outcomes, led by Pamela Hinds, PhD, to provide an important adjunct to the traditional endpoints of phase I studies, thereby facilitating prioritization of new treatments for phase II and III studies. Eugene Hwang, MD, is the Principal Investigator for a multi-institutional phase II study of vinorelbine for recurrent or progressive low-grade gliomas. Brian Rood, MD, is Principal Investigator for a phase II study of metronomic chemotherapy for recurrent/progressive brain tumors.

Other Experimental Therapeutics Research

Children’s National investigators also develop phase I and II studies that are administrated outside the programs of COG and the PBTC. Dr. Holly Meany is the Principal Investigator of a phase I study of sorafenib and irinotecan for recurrent solid tumors and brain tumors. This study is funded by grants from the Clinical and Translational Science Institute at Children’s National (CTSI-CN), the American Society of Clinical Oncology (ASCO), and the Pablove Foundation. The Children’s Hospital of Philadelphia, Boston Children’s Hospital/Dana Farber Cancer Institute, and the National Cancer Institute are participating in this Children’s National-led study. Integrated is a study of Patient Reported Outcomes, led by Dr. Hinds, to provide an important adjunct to the traditional endpoints of phase I studies, thereby facilitating prioritization of new treatments for phase II and III studies. Dr. Hwang is the Principal Investigator for a multi-institutional phase II study of vinorelbine for recurrent or progressive low-grade gliomas. Dr. Rood is the Principal Investigator for a phase II study of metronomic chemotherapy for recurrent/progressive brain tumors. Children’s National also participates in the Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium (TACL), the Cooperative Ependymoma Research Network (CERN), and the Childhood Cancer Survivor Study (CCSS). Shana Jacobs, MD, leads the Palliative Care/Cancer Control Program and under her leadership, Children’s National has developed several studies aimed at improving quality of life during cancer treatment including a massage therapy study.

Faculty members of the Children's Oncology Program: